Ciltacabtagene autoleucel (cilta-cel; Carvykti) for multiple myeloma has a new boxed warning for immune effector ...

免预处理，一月几乎完全清除致病细胞，CAR-T治疗自免疾病结果亮眼Cabaletta Bio近日公布其RESET-PV临床试验的初步数据。该试验旨在评估其在研自体CAR-T细胞疗法rese-cel（resecabtagene ...

The FDA adds a new boxed warning for immune effector cell-associated enterocolitis with Carvykti, but says the overall ...

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Early research has identified several antigens that could ...

(Reuters) -Drugmaker Bristol Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital ...

BCMA-targeting CAR T-cell therapy shows similar efficacy and safety for REMPs and non-REMPs, despite access disparities. REMPs experience reduced access to CAR T therapy, with significant drops in ...

Physicians from Bochum have used a cancer treatment method to treat severe autoimmune diseases. A team of physicians from Bochum are the first to successfully use CAR T-cell therapy to treat two ...

In vivo CD19 CAR T-cell therapy showed promising results in a feasibility study of five patients with refractory systemic ...

The ZUMA-24 study showed outpatient axicabtagene ciloleucel (axi-cel) for DLBCL reduced hospitalization and improved safety profiles. CAR T-cell therapy for DLBCL shows promise in outpatient settings, ...

This report provides a comprehensive analysis of the global CAR-T cell therapy isolator Market, highlighting growth trends, regional dynamics, and key industry drivers. It is published by Towards ...